Published 2 days ago • loading... • Updated 1 day ago

Study: Weight Loss Similar Between Shot, Pill

NEW YORK — Eli Lilly said Tuesday that patients in a latestage trial who had been taking an injectable GLP-1 medication for over a year did not regain significant weight after switching to its new weight-loss pill Foundayo.

8 Articles

Journal Gazette & Times-Courier

+3 Reposted by 3 other sources

Center

Study: Weight loss similar between shot, pill

NEW YORK — Eli Lilly said Tuesday that patients in a latest age trial who had been taking an injectable GLP-1 medication for over a year did not regain significant weight after switching to its new weight-loss pill Foundayo.

1 day ago

Read Full Article

Pharmaphorum

Center

Novo, Lilly trade oral GLP-1 data readouts at ECO

Novo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables.

2 days ago

Read Full Article

borsen.dk

Lilly Trial Draws Headlines – Could Be Good for Novo

Lilly trial draws headlines – could be good for NovoA trial from Novo Nordisk's competitor Eli Lilly draws headlines in international media such as the BBC and Danish media such as DR and TV2 on Wednesday –

2 days ago

Read Full Article

Clinical Trials Arena

Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early responders

This new high dose Wegovy data could help support Novo Nordisk in its bid to claw back market share taken by Eli Lilly in the obesity space.The post Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early responders appeared first on Clinical Trials Arena.

2 days ago

Read Full Article